Background
==========

Many genome-wide association studies (GWAS) have been conducted in the search for specific genetic variants associated with common diseases. In testing for association with common polymorphisms, those variants that were identified were able to explain a modest proportion of disease heritability. This led to the hypothesis that multiple rare variants may play a role in complex disease etiology \[[@B1]\]\[[@B2]\]\[[@B3]\]. The multiple rare variants or common disease/rare variant hypothesis states that multiple rare variants with moderate to high penetrances underlie the susceptibility to a common disease. It is likely that both common and rare genetic variants contribute to disease risk.

Approaches targeted at uncovering associations between common polymorphisms and disease are generally underpowered for detecting the influence of rare variants. To identify disease-associated rare variants, investigators have proposed several methods based on the collapsing of low-frequency single-nucleotide polymorphisms (SNPs) \[[@B4]-[@B7]\].

In this analysis we use the methods proposed by Li and Leal \[[@B4]\] and Morris and Zeggini \[[@B8]\] to identify rare variants, and we use association analysis to identify common variants that confer liability to disease. The rationale behind this collapsing approach is that although the probability that an individual carries more than one rare allele may be low, in aggregate rare alleles may be common enough to account for variation in common traits. The goal is then to test for an association of an accumulation of rare minor alleles with the disease trait, by combining information across multiple variant sites.

We begin our analyses with the collapsing methods and extend the analyses in two ways. First, we use the mean log *p*-value (MLP) \[[@B9]\], which is a method that takes into account information about SNP function and ontologic pathway. The MLP can be thought of as a way to group together SNPs by their functional implication. It was originally developed for the analysis of gene expression data for a better understanding of the underlying mechanisms. Thus, by further analyzing the results of the rare variant collapsing approach using MLP analysis, we exploit both the spatial and the functional associations of SNPs implicated in a disease. Second, we use an empirical approach, stochastic gradient boosting (SGB), to discern groups of SNPs conferring liability to disease. SGB is an ensemble tree-based method \[[@B10]\] that is useful for empirically detecting sets of genes associated with a disease.

Methods
=======

Data
----

Our analyses focus on the case-control data provided to the participants of Genetic Analysis Workshop 17 \[[@B11]\]. We selected the first of 200 simulated replicates for analysis. We conducted the Hardy-Weinberg equilibrium test using PLINK \[[@B12]\] and excluded from further analysis all markers with deviations (*p*-value less than 0.0001 in control subjects). We conducted population stratification analysis by first excluding correlated markers and then using the multidimensional scaling methods in PLINK.

Significant markers
-------------------

We use the collapsing method proposed by Li and Leal \[[@B4]\] and Morris and Zeggini \[[@B8]\] to identify possible variants among rare SNPs. For this analysis we use the CCRaVAT (Case-Control Rare Variant Analysis Tool) software package \[[@B13]\]. The collapsing method is as follows: first, we divide the markers into groups on the basis of predefined criteria (either genes or sliding windows of defined sequence length); next, we collapse marker data based on an indicator variable that shows whether a subject carries any rare variants; and finally, using a Pearson chi-square test, we test the significance of the difference in proportions between case subjects and control subjects who carry rare variant minor alleles. When cell counts are small, we use a Fisher exact test instead.

We consider several approaches for the collapsing criterion, including gene-based collapsing and sliding windows of five different sizes (1 kb, 5 kb, 25 kb, 50 kb, and 100 kb). The resulting *p*-values are recorded for further analysis. In addition, we test the common variant SNPs using the Pearson chi-square test. Again, the resulting *p*-values are retained for further analysis.

MLP approach
------------

We use the MLP approach \[[@B9]\] to incorporate functional and pathway information about genes into our analysis. The MLP analysis was developed in the context of gene expression analysis. The idea is to first assign a statistic (e.g., a *p*-value) to each gene. The genes are mapped onto gene sets or pathways by utilizing gene annotation databases, such as the Kyoto Encyclopedia of Genes and Genomes (KEGG) \[[@B14]\], the Ingenuity Pathway Analysis (IPA) \[[@B15]\], and the Gene Ontology (GO) Biological Processes databases \[[@B16]\]. Permutation tests are used to determine a *p*-value for a gene set and to identify the top set of gene sets.

In our analysis, we explore both rare and common variants. To assign a *p*-value to a gene, we use the results of collapsing and association tests. Thus a gene can have multiple *p*-values associated with it, especially in the rare variant analysis, because the windows overlap. We examine several ways to assign the *p*-value to a gene in order to explore the utility of each, three for rare variants and two for common variants. For rare variants, we use (1) the *p*-value from the association test based on gene-wise collapsing or (2) the minimum *p*-value among association tests based on the collapsing within 5-kb sliding windows located in a gene. This window size is based on the preliminary explorations of varying window sizes ranging from 1 kb to 100 kb. In addition, we use (3) the mean log *p*-value among association tests based on the collapsing within 5-kb sliding windows located in a gene. For common variants, we use either (1) the minimum *p*-value among SNPs in a gene or (2) the mean log *p*-value among SNPs in a gene.

We create gene sets, consisting of groups of genes, on the basis of one of the databases (KEGG, IPA, or GO). The gene set statistic is subsequently calculated as the MLP of the gene statistics for each gene set. The permutation procedure described by Raghavan et al. \[[@B9]\] is used to obtain the gene set *p*-value. The gene sets are rank-ordered by *p*-value. We examine the top 20 sets and present the top 6 sets in this report.

Stochastic gradient boosting
----------------------------

SGB \[[@B10]\] is an ensemble tree-based method that uses an independently drawn random sample of individuals and SNPs to construct a small tree, typically containing 2 to 12 terminal nodes. The tree is grown as a result of recursively partitioning a node and contributes a small portion to the overall model. Each consecutive tree is built for the prediction residuals (from all preceding trees) of an independently drawn random sample. The final SGB model and its prediction perform by combining weighted individual tree contributions, with weight being a shrinkage parameter appropriately selected to reduce overfitting.

The SGB method produces a variable importance measure that can be used to identify top predictors. For tree methods variable importance scores show the relative contribution of each of the variables to predicting the outcome. For ensemble methods, such as SGB, the variable importance scores are averaged across all trees.

We apply the SGB method, using TreeNet, developed by Salford Systems \[[@B17]\], to the data consisting of the first replicate of the affected phenotype, multidimensional scaling components, environmental predictors (Age, Smoke, and Sex), and SNPs. We start with a set of the top common and rare SNPs passed from the collapsing approach and association tests. We then use the set of all SNPs provided in the GAW17 dataset.

Results
=======

The initial data analysis of minor allele frequencies (MAFs) in the case-control data showed 3,224 rare variants (MAF between 1% and 5%) and 18,131 very rare variants (MAF less than 1%). There were 209 (30%) affected case subjects and 488 (70%) unaffected control subjects. Twenty-nine percent of males and thirty-one percent of females were affected. Smoking differed with case status. Smoking was prevalent in 35.9% of the affected subjects, in contrast to 21.7% of the unaffected subjects. After filtering, the data set included 22,615 SNPs. The population stratification results (the first two components) are shown in Figure [1](#F1){ref-type="fig"}. Three clusters were identified, corresponding to three populations. The resulting dimensions were carried forward for stratification.

![Plot of the first two components of multidimensional scaling](1753-6561-5-S9-S94-1){#F1}

We performed collapsing for various window sizes (1 kb, 5 kb, 25 kb, 50 kb, and 100 kb) as well as gene-wise collapsing. The Manhattan plot of *p*-values produced by the collapsing approach for 5-kb sliding windows is shown in Figure [2](#F2){ref-type="fig"}. The results from the 5-kb analysis were carried into further analyses.

![Manhattan plot of collapsing approach *p*-values for 5-kb sliding window](1753-6561-5-S9-S94-2){#F2}

We used the MLP approach to identify the top gene sets based on the KEGG, IPA, and GO databases. We examined the results from the MLP analysis using IPA pathways in greater detail, because this was the database used to simulate the GAW17 data. The top 20 gene sets were examined. Results for the top six sets are summarized in Table [1](#T1){ref-type="table"}. The three gene statistics for rare variants and the two gene statistics for common variants described in the "MLP Approach" subsection of the Methods section are presented. The top gene sets based on the minimum of window *p*-values shows the Notch, Hypoxia, Nitric Oxide, and vascular endothelial growth factor (VEGF) signaling pathways. Both the VEGF and the Notch signaling pathways control initiation and differentiation in angiogenesis, a process leading to blood vessel formation or remodeling. The VEGF pathway is also among the top 15 pathways identified using the KEGG database and the same statistic (results not shown).

###### 

Major IPA pathways identified by the MLP approach using five statistics for rare and common variants and their corresponding *p*-values

  Statistic                                                            Top 6 pathways selected                                           *p*-value
  -------------------------------------------------------------------- ----------------------------------------------------------------- -----------
  Rare variants                                                                                                                          
                                                                                                                                         
  Gene-wise collapsing                                                 1\. Androgen and estrogen metabolism                              0.0006
                                                                       2\. Sphingolipid metabolism                                       0.0006
                                                                       3\. Phenylalanine metabolism                                      0.0015
                                                                       4\. Death receptor signaling                                      0.002
                                                                       5\. Stilbene, coumarine, and lignin biosynthesis                  0.0036
                                                                       6\. TWEAK signaling                                               0.0043
                                                                                                                                         
  Minimum *p*-value of 5-kb sliding window collapsing within a gene    1\. Notch signaling                                               0.0248
                                                                       2\. Hypoxia signaling in the cardiovascular system                0.0403
                                                                       3\. Nitric oxide signaling in the cardiovascular system           0.0409
                                                                       4\. VEGF signaling                                                0.0585
                                                                       5\. Glutamate receptor signaling                                  0.0642
                                                                       6\. Glutamate metabolism                                          0.0741
                                                                                                                                         
  Mean log *p*-value of 5-kb sliding window collapsing within a gene   1\. Cyanoamino acid metabolism                                    0.0032
                                                                       2\. Ubiquinone biosynthesis                                       0.0148
                                                                       3\. Nitrogen metabolism                                           0.0267
                                                                       4\. Alanine and aspartate metabolism                              0.0392
                                                                       5\. GABA receptor signaling                                       0.0423
                                                                       6\. FXR/RXR activation                                            0.0438
                                                                                                                                         
  Common variants                                                                                                                        
                                                                                                                                         
  Minimum *p*-value among SNPs                                         1\. Apoptosis signaling                                           0.0083
                                                                       2\. Pyrimidine metabolism                                         0.0232
                                                                       3\. CNTF signaling                                                0.0429
                                                                       4\. FLT3 signaling in hematopoietic progenitor cells              0.0601
                                                                       5\. Role of NANOG in mammalian embryonic stem cell pluripotency   0.0847
                                                                       6\. EGF signaling                                                 0.0908
                                                                                                                                         
  Mean log p-value for SNPs in a gene                                  1\. Pyrimidine metabolism                                         0.0021
                                                                       2\. CNTF signaling                                                0.0127
                                                                       3\. Melanocyte development and pigmentation signaling             0.0221
                                                                       4\. JAK/Stat signaling                                            0.0327
                                                                       5\. IL-15 signaling                                               0.0356
                                                                       6\. FLT3 signaling in hematopoietic progenitor cells              0.045

We applied the SGB approach to the data containing preselected SNPs, population stratification results, and environmental variables. We used TreeNet to perform the SGB. We built 5,000 trees (iterations) with a maximum of 8 nodes. We chose a shrinkage parameter of 0.01 as appropriate for a data set of this dimension \[[@B18],[@B19]\]. The top set of SNPs was selected using a variable importance measure of 7.00 as a cutoff threshold. The corresponding genes were also recorded. The results of the SGB approach are shown in Table [2](#T2){ref-type="table"}. The table contains the top SNPs selected and their corresponding genes. The results that match the simulated model are shown in bold. The SGB analyses using the complete set of SNPs did not show an improvement over prior runs (results not shown).

###### 

Top SNPs and corresponding genes identified using the SGB approach

          Top SNPs identified (from highest to lowest variable importance)                                                                                           
  ------- ------------------------------------------------------------------ ---------------- ------------ ------------- ------------ ------------- ---------------- ----------------
  SNPs    **C13S523**                                                        C9S3621          C6S6142      C5S237        C9S4860      C22S1374      C2S5630          C11S60
          C13S905                                                            **C1S6542**      C7S2893      C19S282       C6S1097      C10S2632      C2S955           C14S784
          C1S5779                                                            C7S2446          C9S1469      C12S4668      C2S1087      C2S2148       C1S10506         C6S2129
          C15S3343                                                           C12S4188         C14S1863     C2S4601       C6S2469      C10S2533      C19S609          C10S5515
          C1S5530                                                            C17S3017         C9S1225      **C13S522**   C12S3028     C5S3461       C19S1762         C1S9584
          C19S1849                                                           C9S4013          C22S1405     C12S622       C12S7056     C2S7558       C16S3421         C12S552
          C2S4407                                                            C1S996           C22S1351     C20S2310      C22S1158     C15S4060      C17S1262         C3S1305
          C7S158                                                             C10S387          C17S2377     C7S1877       C1S9718      C10S4422      C4S2872          C7S3971
          C2S689                                                             C8S3322          C10S6566     C14S20        C7S1076      C11S3224      C1S7413          C22S146
          C8S4238                                                            C8S4028          C18S2322     C6S6040       C12S5220     C6S6177       C19S3382         C19S2528
          C1S9506                                                            C4S4283          C12S3528     C11S2585      C17S2376     C12S5446      C17S4841         C1S10200
          C4S2239                                                            C7S3613          C5S4072      C11S6503      C11S4881     C1S10800      C9S123           C2S7414
          C2S1139                                                            C3S3962          C7S3490      C10S5783      C11S1683     C9S2613       C11S2532         C7S4111
          C18S2310                                                           C2S4079          C6S2366      C8S627        C2S6985      C1S7941       **C11S5292**     C4S4339
          C3S3938                                                            **C6S5380**      C22S875      C1S7092       C7S2590      C11S2871      C6S2216          C6S5677
          C7S4646                                                            C8S850           C8S271       C4S2296       C10S386      C9S5111       C15S3138         C1S7427
          C17S3510                                                           C3S96            C22S385      C1S3900       C3S4638      C21S672       C1S1388          C10S2683
          C13S1168                                                           C7S3697          C2S4909      C11S1280      C2S2154      C12S4591      C3S1176          C22S2039
          C11S3320                                                           C2S873           C9S3100      C2S7390       C12S5526     C11S1599      C6S4552          C1S10256
          C10S3243                                                           C12S5510         C4S2678      C4S2970       C2S8207      C16S560       C6S7138          C17S321
          C20S1844                                                           C12S5445         C10S2670     C1S4009       C17S2026     C9S3554       C13S1660         C14S590
          C10S6432                                                           C9S759           C19S4625     C1S9511       C8S934       C6S4242       C18S1560         C4S97
          C15S3744                                                           C7S397           C19S4658     C12S4534      C9S2083      C19S5271      C7S3898          C1S4838
          C9S1607                                                            C4S3834          C11S5644     C15S2848      C10S3777     C3S3657       C14S122          C14S3426
          C16S1482                                                           C4S3076          C9S2542      C2S6995       C21S778      C9S1835       C15S3559         C8S3416
          C5S2032                                                            C1S10813         C10S5690     C1S3676       C6S4400      C13S163       C22S645          C12S3039
          C1S10164                                                           C6S7164          C22S1222     C4S649        C19S277      C1S7408       C1S1542          C4S186
                                                                                                                                                                     
  Genes   *TNFRSF25*                                                         *AHSA2*          *ADH1B*      *GPR85*       *OR13C5*     *SYTL2*       *PSME2*          *PTPRS*
          *ARHGEF10L*                                                        *RGPD3*          *C4ORF33*    *PTPRZ1*      *CDK5RAP2*   ***PDGFD***   *VTI1B*          *OR10H3*
          *KIF17*                                                            *RGPD4*          *TKTL2*      *PAX4*        *STOM*       *EXPH5*       *BEGAIN*         *CYP4F2*
          *PDE4B*                                                            *ACVR1C*         *ANP32C*     *SMO*         *GOLGA1*     *OR8D4*       *PAQR5*          *ZNF486*
          *PTGER3*                                                           *LY75*           *PLEKHG4B*   *ZC3HC1*      *BRD3*       *CLEC2D*      *TSPAN3*         *NPHS1*
          *MSH4*                                                             *PPIG*           *ZNF474*     *AKR1B1*      *CARD9*      *KLRK1*       *ADAMTS7*        *ZNF576*
          *STXBP3*                                                           *WDR75*          *ABLIM3*     *SLC37A3*     *ECHDC3*     *OR6C1*       *ALPK3*          *LYPD5TMC4*
          *HIPK1*                                                            *LOC729332*      *FOXI1*      *GATA4*       *ERCC6*      *OR6C65*      *SLC28A1*        *C20ORF32*
          *VTCN1*                                                            *UGT1A10*        *PGBD1*      *TNFRSF10D*   *PGBD3*      *SRGAP1*      *AKAP13*         *PRIC285*
          ***ARNT***                                                         *COL6A3*         *BAT2*       *CDCA2*       *HKDC1*      *PLXNC1*      *ZNF213*         *PIGP*
          *ADAM15*                                                           *MTERFD2*        *SLC44A4*    ***PTK2B***   *MAT1A*      *C12ORF63*    *USP31*          *ETS2*
          *OR10J1*                                                           *CRELD1*         *PSMB8*      *EXT1*        *CYP2C8*     *CHPT1*       *LOC100132786*   *HIRA*
          *OR10J5*                                                           *LOC100130135*   *MDN1*       *SAMD12*      *SORCS1*     *TRAFD1*      *TRPV3*          *ARVCF*
          *UAP1*                                                             *SETD2*          ***VNN1***   *MLZE*        *CASP7*      *CAMKK2*      *KCNJ12*         *TOP3B*
          *LRRN2*                                                            *GOLGB1*         *FUCA2*      *TG*          *DCLRE1A*    *ANAPC5*      *SLFN13*         *SUSD2*
          *NUAK2*                                                            *TMCC1*          *UTRN*       *ANKRD15*     *TACC2*      *ZNF26*       *PIP4K2B*        *SEC14L3*
          *IKBKE*                                                            *TRPC1*          *AGPAT4*     *PDCD1LG2*    *ATHL1*      *TNFRSF19*    *BRCA1*          *SMTN*
          *LAMB3*                                                            *CRIPAK*         *PMS2*       *AQP3*        *GALNTL4*    ***FLT1***    *FAM117A*        *LIMK2*
          *DUSP10*                                                           *GRK4*           *TSPAN13*    *C9ORF131*    *HPS5*       *TRPC4*       *RECQL5*         *LOC100132621*
          *KIAA0133*                                                         *AFAP1*          *NPC1L1*     *NPR2*        *NELL1*      *FREM2*       *HRH4*           
          *ARL6IP2*                                                          *PF4V1*          *NCF1*       *POLR1E*      *OR8H1*      *PIBF1*       *B4GALT6*        
          *OXER1*                                                            *STBD1*          *FBXO24*     *SMC5*        *OR9G4*      *RNASE6*      *MCART2*         
          *FSHR*                                                             *FAM13A1*        *FBXL13*     *C9ORF79*     *OR4D9*      *FLJ10357*    *ZNF57*          
          *BCL11A*                                                           *PDLIM5*         *RELN*       *ROR2*        *AHNAK*      *ACIN1*       *ZNF77*          

Boldface indicates results that match the simulated model.

The MLP approach correctly placed the VEGF signaling pathway and the two pathways related to the cardiovascular system (Hypoxia and Nitric Oxide) among the top six pathways. There are only 5 (out of 216) SNPs correctly identified using the SGB approach; their MAFs range from 0.2% to 17%. Most of the SNPs (211) placed in the top list are false positives.

Discussion and conclusions
==========================

Traditionally, GWAS test for association of disease with common polymorphisms. Polymorphisms with population frequencies of 5% or more could be tested directly or indirectly for association with disease risk or quantitative traits, and GWAS have identified many genetic variants associated with disease traits. Replication of these results has not been consistently successful. More recently, methods have been proposed to identify multiple rare variants with small individual effect sizes that may be implicated in complex multigenic diseases. These methods are based on grouping rare variants by their physical proximity in order to combine information across them. According to Hirschhorn \[[@B20]\], one of the primary goals of GWAS is to discover the biologic pathways underlying polygenic diseases.

The MLP method is an effort in this direction, where both common and rare variants are considered on the basis of their functional implication in disease etiology. Our goal here was to exploit both the spatial and the functional associations of SNPs implicated in a disease to identify the underlying biologic pathways. Pathways used to simulate the affection status in the GAW17 data set were among the top four pathways identified by the MLP approach based on statistic 2 for rare variants. More specifically, the three pathways (Hypoxia, Nitric Oxide, and VEGF) were used to simulate the data. In addition, as explained in what follows, the top four pathways, including the Notch pathway, may be part of a cascade of interrelated pathways. Enriched signaling pathways in our analysis may overlap functionally and indicate processes leading to angiogenesis. Hypoxia signaling can trigger the VEGF cascade in cancer tissue angiogenesis, and the Notch processes downstream from the Hypoxia and VEGF pathways lead to a differentiation of newly formed vessels. Notch signaling can also down-regulate VEGF expression in a feedback loop. Thus the MLP approach based on statistic 2 for rare variants appears to be able to also identify related pathways and may be promising for the discovery of biological pathways implicated in disease etiology by rare variants.

One of the goals of this analysis was to compare results from a variety of functional and pathway databases and from a number of gene statistics. Our results indicate that using the IPA database, the gene statistic that identified the most relevant pathways was the minimum *p*-value derived from collapsing rare variants within 5-kb sliding windows residing in a gene. These results highlight the importance of using the most appropriate pathway database for the analysis, an aspect not explicitly discussed in the literature. Our analysis also indicates that (1) the results can be influenced by the density of coverage of rare variant SNPs in a gene; (2) gene-based collapsing may be too broad and may dilute the underlying information; and (3) using the mean of the window *p*-values may mute the signal considerably. In future work, we will evaluate alternative approaches to mapping SNP-level *p*-values to gene-level *p*-values as well as methods for combining the rare and common variants analyses.

The top pathways identified using the MLP method intersect with the pathways that contain genes from the results of the SGB approach. There are 5 correct SNPs out of 216 residing in 5 correct genes out of 188 corresponding to the top selected SNPs. The large number of false positives may be due to correlation of the SNPs identified by the SGB approach with the true SNPs used in the simulation model. Our current work includes studying methods to bridge the two approaches utilizing the functional information and the statistical correlation, respectively.

Currently, many analytic strategies rely on GWAS with one-SNP-at-a-time analyses. Although this approach has certainly yielded many promising candidates, it requires large samples to mitigate type I errors. One-SNP-at-a-time analyses generally do not take advantage of all the information present in the data, and failure of replication is commonplace. Recent attempts have been made to incorporate information from rare variants into the analysis by aggregating across SNPs that are in close proximity to each other. We have extended this further by leveraging information from SNPs that are either functionally related (MLP approach) or statistically correlated (SGB approach) with the hope of obtaining results that are credible and logically interpretable. These methods would, of course, need to be further evaluated in other data sets and other settings.
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